ClinicalTrials.gg
Active, not recruitingNCT02500849Updated Oct 2, 2026

Safety Study of Zinc Finger Nuclease CCR5-modified Hematopoietic Stem/Progenitor Cells in HIV-1 Infected Patients

A Phase 1 interventional study of SB-728mR-HSPC Infusion 3 days following busulfan conditioning in HIV, sponsored by City of Hope Medical Center. Active, not recruiting at 5 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-02.

Primary conditionAcquired Immunodeficiency Syndrome(the registry's first term)UnverifiedIs this wrong?The registry often attaches Acquired Immunodeficiency Syndrome to studies about something else, and this study's title and listed conditions do not name it. No better condition is named, so the registry's term is kept.

Sponsored by City of Hope Medical Center · Phase 1, Interventional, and Treatment

How we know

Updated Oct 2, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The purpose of the study is to evaluate the safety and feasibility of administering SB-728mR-HSPC after conditioning with busulfan.

Read the detailed description

The objective of the study is to evaluate the safety and feasibility of giving autologous SB-728mR-HSPC to HIV-1 (R5) infected patients who are being treated with cART and have undetectable virus but suboptimal CD4+ cell levels. To strengthen the possibility that CCR5-disrupted HSPCs engraft, patients will receive either a two- or three-day (Cohort 1 or Cohort 2) course of busulfan (dose targeting AUC of 4000 µM/day) before being infused with the genetically modified cells. At 9-12 months after SB-728mR-HSPC infusion, subjects who are aviremic with CD4 cell counts ≥600 cells/µL and have ≥1% CCR5-modified CD4 cells within the peripheral blood detected by pentamer PCR will undergo an ATI.

02

Conditions studied

  • HIV

Keywords

  • Gene therapy
  • Acquired Immunodeficiency Syndrome
  • HIV Infections
  • Retroviridae Infections
  • RNA Virus Infections
  • Virus Diseases
  • Sexually Transmitted Diseases, Viral
  • Sexually Transmitted Diseases
  • Immunologic Deficiency Syndromes
  • Immune System Diseases
  • Busulfan
  • Pharmacologic Actions
03

In context

Acquired Immunodeficiency Syndrome Unverified

3,039 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.

This study's planned enrollment of 12 is below the median of 96 across 2,254 interventional studies indexed under Acquired Immunodeficiency Syndrome.

Browse Acquired Immunodeficiency Syndrome studies →

Lead sponsor

City of Hope Medical Center is the lead sponsor of 677 studies on the registry; 181 are open to participants now.

Of its 31 completed or terminated interventional studies of FDA-regulated products, 12 (39%) have results posted.

Compared within Acquired Immunodeficiency Syndrome, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Maximum age 75 years for cohort 1 and 65 years for cohort 2.
  • -1 R5 seropositive with no evidence of CXCR4-tropic virus.
  • On cART with undetectable HIV-1 (\<20 gc/ml HIV-1 RNA) for at least 12 months prior to screening evaluations.
  • ≥200 cells/µL and ≤750 cells/µL.
  • No psychosocial conditions that would hinder study compliance and follow-up.
  • Absence of cardiomyopathy, congestive heart failure.

Secondary Eligibility Criteria (for registration):

  • Complete G-CSF/Plerixafor mobilization of HSPC.
  • Collect ≥7.5 x 10\^6 CD34+ cells/kg in two aphereses.
  • The SB-728mR-HSPC product passed all release testing

Exclusion criteria

Exclusion Criteria:

  • Use of AZT or maraviroc in the cART regimen.
  • History of significant hematologic diseases such as leukemia, myelodysplasia, coagulopathy, and thromboembolism.
  • Any AIDS-related opportunistic infection occurring within the past year such as tuberculosis, cryptococcosis and for which treatment has been unsuccessful as determined by the Principal Investigator.
  • AIDS-related syndromes, infectious or otherwise, if perceived to cause excessive risk for morbidity post-HSPC infusion, as determined by the Principal Investigator.
  • Patients with active or infection, i.e., HBV DNA and HCV RNA in blood, are excluded. Those with inactive, but past infection with HBV (positive HBV surface antigen or HBV surface antibody) or inactive HCV (positive HCV antibody), must have no cirrhosis, as determined by abdominal ultrasound with elastography.
  • Active CMV retinitis or other active CMV-related organ dysfunction.
  • CXCR4-tropic virus.
  • Pregnant or nursing women.
  • Any history of -associated encephalopathy; dementia of any kind; seizures in the past 12 months; any perceived inability to directly provide .
  • Participants may not be receiving any other agents, or concurrent biological, chemotherapy, or radiation therapy. Participation in prior investigational drug or medical device study within the previous 45 days.
  • Current or history of immunomodulatory agent or use.
  • Prior therapy with HIV vaccine or gene therapy product.
  • History of alcohol or substance abuse for the previous 12 months.
  • Participants with active . However, participants with skin cancers, namely basal cell or squamous cell carcinoma, and malignancies treated with curative intent having no known active disease present for ≥2 years, may be eligible.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    Cohort 1:

    target busulfan AUC levels: 8,000 µM\*min (+/- 1,000)

    Genetic: SB-728mR-HSPC Infusion 3 days following busulfan conditioning

  • Experimental
    Cohort 2:

    busulfan AUC levels: 12,000 µM\*min (+/- 1,000)

    Genetic: SB-728mR-HSPC Infusion 3 days following busulfan conditioning

Interventions

  • GeneticSB-728mR-HSPC Infusion 3 days following busulfan conditioning

    Also known as: busulfan

06

What researchers measure

Primary outcomes

  1. Toxicity in subjects who received SB-728mR-HSPC after each busulfan dose level

    Time frame: 18 months

Secondary outcomes

  1. Number of CD34+ HSPC collected, gene modified, and released throughout the manufacturing process

    Time frame: Approximately first 1-2 months on study

Other outcomes

  1. Detection of CCR5 modified HSPC in bone marrow

    Time frame: Up to Month 12

  2. Time to hematological recovery as measured by neutrophil and platelet engraftment time

    Time frame: Up to Year 5

  3. Changes in CD4+ T-cell percentage after SB-728mR-HSPC infusion

    Time frame: Up to Year 5

  4. Changes in CD4+ T-cell number after SB-728mR-HSPC infusion

    Time frame: Up to Year 5

  5. Changes in CD4/CD8 ratio after SB-728mR-HSPC infusion

    Time frame: Up to Year 5

  6. Detection of CCR5-modified PBMC in blood over time

    Time frame: Up to Year 5

  7. HIV-1 RNA levels in plasma during the treatment interruption of antiretroviral medicines

    Time frame: ATI Day 0 and weeks 2, 4, 6, 8, 10, 12, 14, 16 and 28

  8. Longitudinal changes of proviral DNA in PBMC

    Time frame: 18 months

  9. Pharmacokinetic analysis of busulfan (AUC levels)

    Time frame: pre-busulfan and at 15, 30, 60, 180 and 240 min after end of infusion

07

Study locations

5 sites
08

References and documents

Publications

  • DiGiusto DL, Cannon PM, Holmes MC, Li L, Rao A, Wang J, Lee G, Gregory PD, Kim KA, Hayward SB, Meyer K, Exline C, Lopez E, Henley J, Gonzalez N, Bedell V, Stan R, Zaia JA. Preclinical development and qualification of ZFN-mediated CCR5 disruption in human hematopoietic stem/progenitor cells. Mol Ther Methods Clin Dev. 2016 Nov 9;3:16067. doi: 10.1038/mtm.2016.67. eCollection 2016. PubMed 27900346 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2016 (actual). Primary completion is estimated for Jul 2027, 136 months after the start.

Of 63 non-industry phase 1 interventional studies under Acquired Immunodeficiency Syndrome, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 39. This study's planned 136 months is above that.

Counting every sponsor, half of 139 studies reached it within 14 months; a quarter within 4 and three quarters within 28.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 2, 2026: primary completion Aug 2026 → Jul 2027 and completion Aug 2026 → Jul 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2015
First posted
Jul 17, 2015
StartActual
Mar 10, 2016
Primary completionEst.
Jul 23, 2027was Aug 2026
CompletionEst.
Jul 23, 2027was Aug 2026
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 24, 2026→Jul 23, 2027
Oct 2, 2026
Study completion
Aug 24, 2026→Jul 23, 2027
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Primary completion Aug 24, 2026→Jul 23, 2027
    Study completion Aug 24, 2026→Jul 23, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02500849
Collaborators
Sangamo Therapeutics, California Institute for Regenerative Medicine (CIRM)
Responsible party
Sponsor
First posted
Jul 17, 2015
Start date
Mar 10, 2016
Primary completion
Jul 23, 2027 (estimated)
Completion
Jul 23, 2027 (estimated)
Last update
Oct 2, 2026

Study contacts

Amrita Y. Krishnan, MD
principal investigator · City of Hope Medical Center

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion